177Lu-J591 is made up of two compounds called J591 and 177Lutetium (177Lu) that are joined
together by a connecting molecule called "DOTA". J591 is a monoclonal antibody, or a type of
protein. 177Lu is a radioactive molecule that is being tested for the possible treatment of
cancer when joined to monoclonal antibodies. J591 attaches to a protein called prostate
specific membrane antigen (PSMA) found in the body. PSMA is mostly found in normal and
cancerous prostate cells. In addition, however, PSMA has also been found on the vasculature
(blood vessels) that supply multiple types of cancer including colorectal, kidney, bladder,
head and neck, breast, non-small cell lung, pancreas, ovary, esophagus and gliomas.
We hope that 177Lu-J591 will seek out blood vessels that supply these tumors and deliver a
dose of radiation (from the 177Lu molecule) to the areas of cancer, without affecting target
blood vessel that are not associated with the cancer.
Zirconium-89 (89Zr) is a radioactive tracer that allows special scans to be performed prior
to administration of the study drug to determine where the antibody goes in the body and to
screen the tumor's blood vessels to see if they attract J591. Again, DOTA is used to join the
radioactive material to J591. 89Zr-J591 is not being given to treat cancer.
- Histologically, or cytologically documented, advanced stage, malignant adult solid
tumors (except prostate cancer) that are refractory to, or recurrent from, standard
therapy or for which no curative standard therapy exists. This will include, but is
not limited to patients with cancers of the kidney, urothelium, head and neck, breast,
non-small cell lung, colorectal, pancreas, ovary, esophagus and gliomas.
- Metastatic or recurrent solid tumor malignancy defined by abnormal CT, MRI, PET scan,
CXR and/or bone scan
- Progressive disease manifest by: Development of new lesions or an increase in size of
preexisting lesions on imaging study or by physical examination.
- Subjects must have recovered from the acute toxicities of any prior therapy, and not
received chemotherapy, radiation therapy or other investigational anticancer
therapeutic drug for at least 4 weeks prior to J591 administration in this trial
- All subjects must have archived or current tissue (from a primary or metastatic focus)
available for PSMA determination.
- Subjects on bisphosphonate therapy or denosumab must be on a stable dose and must have
started therapy > 4 weeks prior to protocol therapy.
- Subjects will be informed as to the potential risk of procreation while participating
on this trial and will be advised to use effective contraception during the entire
study period. Females of child-bearing potential must have a negative pregnancy test.
- Use of platelet transfusions within 4 weeks of treatment.
- Use of hematopoietic growth factors within 4 weeks of treatment.
- Prior cytotoxic chemotherapy and/or radiation therapy within 4 weeks of treatment.
- Prior radiation therapy encompassing >25% of skeleton.
- Prior treatment with 89Strontium or 153Samarium containing compounds (e.g. Metastron®,
- Platelet count <150,000/mm3 or history of platelet count abnormality or dysfunction.
- Absolute neutrophil count (ANC) <2,000/mm3
- Hematocrit <30 percent or Hemoglobin < 10 g/dL
- Abnormal coagulation profile (PT or INR, PTT) > 1.3x upper limit of normal (ULN)
unless on therapeutic anticoagulation
- Serum creatinine > 2x ULN
- AST (SGOT) >2.5x ULN
- Bilirubin (total) >1.5x ULN; subjects with known Gilbert's syndrome are eligible if
direct bilirubin is within institutional normal limits
- Active serious infection
- Active angina pectoris or NY Heart Association Class III-IV
- ECOG Performance Status > 2
- Deep vein thrombosis and/or pulmonary embolus within 1 month of enrollment.
- Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or
hematological organ systems which might preclude completion of this study or interfere
with determination of causality of any adverse effects experienced in this study.
- Prior investigational therapy (medications or devices) within 4 weeks of treatment.
- Known history of HIV.
- Known leukemia or myelodysplastic syndrome
- Prior allergic reaction to Gadolinium contrast.
- Life expectancy < 3 months
- If alternative treatments are available, metastatic disease should not be progressing
so as to anticipate the necessity of urgent treatment within 12 weeks of enrollment
based on clinical assessment of the investigator